Literature DB >> 10704552

Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy.

M S Blumenkranz1, K W Woodburn, F Qing, S Verdooner, D Kessel, R Miller.   

Abstract

PURPOSE: To investigate the suitability of lutetium texaphyrin (lu-tex) as a fluorescence imaging agent in the delineation of retinal vascular and choroidal vascular diseases. The utilization of an efficient fluorescent molecule that is also a photosensitizer represents a unique opportunity to couple diagnosis and therapy.
METHODS: Fundus fluorescence angiography comparing lu-tex (motexafin lutetium, Optrin, Pharmacyclics Inc, Sunnyvale, California) with the conventional angiographic dyes, sodium fluorescein, and indocynanine green (ICG), was performed on the eyes of normal and laser-injured New Zealand white rabbits. Plasma pharmacokinetic data and plasma protein binding were assessed in addition to light microscopy of the retina in both imaged and laser-injured eyes.
RESULTS: Normal retinal and choroidal vasculature was well delineated by lu-tex angiography. Experimentally induced choroidal and retinal vascular lesions were enhanced by lu-tex and demonstrated different staining patterns than fluorescein or ICG, particularly at the margins of the lesions. Lu-tex cleared rapidly from the plasma, with 39.7% bound to the high-density lipoprotein (HDL) fraction while 15.8% was bound to the low-density lipoprotein (LDL) fraction. No evidence of retinal toxicity after dye administration was observed by either ophthalmoscopy and fundus photography or by light microscopy.
CONCLUSION: Lu-tex angiography is a potentially valuable method for retinal vascular and choroidal vascular evaluation, and it has advantages over fluorescein and ICG angiography. The same agent could conceivably be used for both the identification of abnormal vasculature and subsequent photodynamic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704552     DOI: 10.1016/s0002-9394(99)00462-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Effect of chirality on cellular uptake, imaging and photodynamic therapy of photosensitizers derived from chlorophyll-a.

Authors:  Avinash Srivatsan; Paula Pera; Penny Joshi; Yanfang Wang; Joseph R Missert; Erin C Tracy; Walter A Tabaczynski; Rutao Yao; Munawwar Sajjad; Heinz Baumann; Ravindra K Pandey
Journal:  Bioorg Med Chem       Date:  2015-04-09       Impact factor: 3.641

3.  Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery.

Authors:  Kishore Cholkar; Sriram Gunda; Ravinder Earla; Dhananjay Pal; Ashim K Mitra
Journal:  AAPS PharmSciTech       Date:  2014-11-26       Impact factor: 3.246

Review 4.  Age-related macular degeneration: epidemiology and optimal treatment.

Authors:  Morten la Cour; Jens Folke Kiilgaard; Mogens Holst Nissen
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Physically facilitating drug-delivery systems.

Authors:  Jorge I Rodriguez-Devora; Sunny Ambure; Zhi-Dong Shi; Yuyu Yuan; Wei Sun; Tao Xui
Journal:  Ther Deliv       Date:  2012-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.